ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis

Cancer Research

Volumn 71, Issue 11, 2011, Pages 3941-3951

  Cook, Rebecca S ^a   Garrett, Joan T ^a   Sánchez, Violeta ^a   Stanford, Jamie C ^a   Young, Christian ^a   Chakrabarty, Anindita ^a   Rinehart, Cammie ^a   Zhang, Yixian ^b   Wu, Yaming ^b   Greenberger, Lee ^b   Horak, Ivan D ^b   Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b Enzon Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CRE RECOMBINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EZN 3920; EZN 4455; GEFITINIB; LAPATINIB; LOCKED NUCLEIC ACID; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; VIRUS MIDDLE T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; VIRUS ONCOGENE;

ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 79957915754     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3775     Document Type: Article

References (49)

1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19. (Pubitemid 44100518)
2. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5. (Pubitemid 41351083)
3. Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006;208:350-5. (Pubitemid 43210521)
4. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81. (Pubitemid 39446895)
5. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-8. (Pubitemid 40525186)
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
7. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7. (Pubitemid 27148818)
8. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008;13:215-23.
9. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007;12:104-7. (Pubitemid 47199129)
10. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74. (Pubitemid 46962095)
11. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
12. Bolen JB, Amini S, DeSeau V, Reddy S, Shalloway D. Analysis of polyomavirus middle-T-antigen-transformed rat cell variants expressing different levels of pp60c-src. J Virol 1987;61:1079-85. (Pubitemid 17044019)
13. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7:389-97. (Pubitemid 46652484)
14. Schaffhausen BS, Roberts TM. Lessons from polyoma middle T antigen on signaling and transformation: a DNA tumor virus contribution to the war on cancer. Virology 2009;384:304-16.
15. Dilworth SM. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer 2002;2:951-6. (Pubitemid 37328896)
16. Ichaso N, Dilworth SM. Cell transformation by the middle T-antigen of polyoma virus. Oncogene 2001;20:7908-16. (Pubitemid 33135317)
17. Rauh MJ, Blackmore V, Andrechek ER, Tortorice CG, Daly R, Lai VK, et al. Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein. Mol Cell Biol 1999;19:8169-79. (Pubitemid 30414011)
18. Webster MA, Hutchinson JN, Rauh MJ, Muthuswamy SK, Anton M, Tortorice CG, et al. Requirement for both Shc and phosphatidylinositol 30 kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 1998;18:2344-59. (Pubitemid 28152681)
19. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008;118:64-78.
20. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-26. (Pubitemid 37310040)
21. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A 1989;86:9193-7. (Pubitemid 20010391)
22. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003;100:8933-8. (Pubitemid 36899201)
23. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995;10:1813-21.
24. Hellyer NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 1998;333:757-63. (Pubitemid 28398546)
25. Carraway KL 3rd, Soltoff SP, Diamonti AJ, Cantley LC. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with ErbB2/Neu and ErbB3. J Biol Chem 1995;270:7111-6.
26. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105-15.
27. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551-9. (Pubitemid 34663517)
28. Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, et al. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol 2002;22:2204-19. (Pubitemid 34224627)
29. Qu S, Rinehart C, Wu HH, Wang SE, Carter B, Xin H, et al. Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis 2006;44:477-86. (Pubitemid 44684994)
30. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, et al. Cre-mediated gene deletion in the mammary gland. Nucl Acids Res 1997;25:4323-30. (Pubitemid 27485212)
31. Guo ZM, Xu K, Yue Y, Huang B, Deng XY, Zhong NQ, et al. Temporal control of Cre recombinase-mediated in vitro DNA recombination by Tet-on gene expression system. Acta Biochim Biophys Sin (Shanghai) 2005;37:133-8. (Pubitemid 40685525)
32. Gunther EJ, Belka GK, Wertheim GB, Wang J, Hartman JL, Boxer RB, et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J 2002;16:283-92. (Pubitemid 34195290)
33. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
34. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63.
35. Liao B, Zhang Y, Kosek J, et al. EZN-3920, an LNA antisense oligonucleotide RNA antagonist, down modulates HER3 expression and PI3K/Akt signaling pathway and enhances antiproliferative effect of gefitinib in tumor cells. In: Poster presentation at the 100th American Association for Cancer Research (AACR) Meeting; 2009 Apr 21; Denver, CO. Abstract 4630.
36. Arora A, Kaur H, Wengel J, Maiti S. Effect of locked nucleic acid (LNA) modification on hybridization kinetics of DNA duplex. Nucleic Acids Symp Ser (Oxf) 2008;52:417-8.
37. Kauppinen S, Vester B, Wengel J. Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics. Handb Exp Pharmacol 2006;173:405-22.
38. Veedu RN, Wengel J. Locked nucleic acid as a novel class of therapeutic agents. RNA Biol 2009;6:321-3.
39. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A 2000;97:5633-8. (Pubitemid 30313770)
40. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75.
41. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68:5878-87.
42. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. (Pubitemid 46799492)
43. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, et al . An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010;70:2485-94.
44. DeGrendele H. The anti-HER2 monoclonal antibody pertuzumab may be effective in androgen-independent prostate cancer. Clin Prostate Cancer 2003;2:143-5. (Pubitemid 38044660)
45. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010;17:298-310.
46. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44.
47. Kristjansdottir K, Dizon D. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. Expert Opin Biol Ther 2010;10:243-50.
48. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340-8. (Pubitemid 351521808)
49. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37. (Pubitemid 33674041)